In the meta-analysis, we found the minor allele of FCGR3A (rs396991) to be associated with poor response to TNFi and infliximab alone when pooling all CIDs together; similarly, this was observed for RA and IBD alone but not for psoriasis. This evidence concerns the gene FCGR3A and inflammatory bowel disease.